SciELO - Scientific Electronic Library Online

 
vol.36 número2Caracterización de los recién nacidos con síndrome de down según condiciones de salud, demográficas y sociales en Medellín del periodo 2015 a 2019El índice de fragilidad y sus características en ensayos clínicos aleatorizados de diabetes mellitus índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


CES Medicina

versión impresa ISSN 0120-8705

Resumen

RAMIREZ-RINCON, Álex et al. Pharmacological treatment of the patient living with type 2 diabetes mellitus. CES Med. [online]. 2022, vol.36, n.2, pp.81-105.  Epub 30-Sep-2022. ISSN 0120-8705.  https://doi.org/10.21615/cesmedicina.6672.

Introduction:

the approach to the patient with diabetes has changed over the past decade. Some years ago, the primary goal of treatment was to achieve a certain level of A1c as a marker of glucose control. Now, with new molecules in the market that can modify the disease and its complications the treatment is focused on the individual patient, his micro and macrovascular complications and the risk of cardiovascular, heart failure and renal complications. In this review of the literature, we expose some questions that need to be solved when approaching the treatment of a patient with type 2 diabetes.

Methods:

we reviewed local and international guidelines on the treatment of type 2 diabetes.

Results:

we reviewed guidelines in the treatment of diabetes, local guidelines; Asociación Colombiana de Endocrinología, Asociación Colombiana de Medicina Interna, Asociación Colombiana de Nefrología, Sociedad Colombiana de Cardiología y Cirugía Cardiovascular. International guidelines; American Diabetes Association, American Association of Clinical Endocrinology, European Association for the Study of Diabetes y European Society of Cardiology Additionally, we revised clinical trial that support the use of the different drugs that are recommended by the guidelines as first, second- or third-line treatment.

Conclusion:

as clinicians we are expected to give the patient an individualized approach, based on their own comorbidities, risk of cardiovascular and renal disease and risk of hypoglycemia guided by national and international guidelines and latest clinical trial that support our approach.

Palabras clave : Type 2 Diabetes Mellitus; treatment; cardiovascular diseases; heart failure; obesity; chronic renal failure.

        · resumen en Español     · texto en Español     · Español ( pdf )